GENE ONLINE|News &
Opinion
Blog

2022-09-29| Trials & Approvals

Sanofi and Regeneron’s Dupixent Snags its Tenth Approval From the FDA

by Reed Slater
Share To
Dupixent, the monoclonal antibody jointly developed by Sanofi and Regeneron, is keeping its momentum going with its third FDA-approved indication this year and its tenth since 2017. The latest indication is reserved for adults with the chronic skin disease, prurigo nodularis, making it the first and only drug indicated for the disease. The FDA based its decision on two Phase 3 trials demonstrating clinically significant positive data. 

It's free! Log in now to read

LOG IN SUBSCRIBE NOW
LATEST
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
READ MORE
EVENT
2023-06-02
2023 ASCO annual meeting
Chicago, USA
2023-06-05
Redefining Early Stage Investments (RESI) 2023 conference series – RESI Boston
Boston, USA
2023-07-26
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023-09-06
2023 Bio Asia Pacific
Bangkok, Thailand
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top